The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.

ABSTRACT:

Background and aims

Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investigated the effects of regorafenib in experimental models without HCC.

Methods

Fibrosis (in vivo and in vitro), inflammation, liver damage (aminotransferases), angiogenesis (matrigel implantation) and in vivo systemic and portal hemodynamics were assessed in different mouse and rat models (bile duct ligation, CCl₄, partial portal vein ligation) after acute and chronic treatment with regorafenib.

Results

Long-term treatment with regorafenib impro

SUBMITTER: Uschner FE 

PROVIDER: S-EPMC6281422 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature